NCT01097044View on ClinicalTrials.gov

Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Erythropoietic Protoporphyria
Interventions
DRUG

Afamelanotide

One 16mg subcutaneous implant every 2 months for 6 months. (3 implants in total)

DRUG

Placebo

One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)

Trial Locations (6)

10029

Mt. Sinai, New York

29203

Carolina's Medical Center Cannon Research, Charlotte

35294

University of Alabama, Birmingham

77555

University of Texas, Galveston

84132

University of Utah, Salt Lake City

94143

University of California, San Francisco, San Francisco

Sponsors
All Listed Sponsors
lead

Clinuvel Pharmaceuticals Limited

INDUSTRY